Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC5298 Uck2-in-135546812 Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors
DCC5299 Uck2-in-20874830 Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors
DCC5300 ucl-1972 Histamine H3 Receptor Antagonist in Treatments of Cognition Disorders
DCC5301 Ucl-2190 Hydrogen Maleate The first potent nonimidazole H3 receptor antagonist (pKi=8.40)
DCC5302 Ucm-05194 Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), Showing Efficacy in Neuropathic Pain Amelioration
DCC5303 Ucm-1336 Novel potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor, improving survival in Ras-driven acute myeloid leukemia
DCC5304 Ucm710 Dual inhibitor of fatty acid amide hydrolase (FAAH) and α/β hydrolase domain 6 (ABHD6)
DCC5305 Ucn-02 Stereoisomer of UCN-01, inhibiting protein kinase C with a slightly reduced potency than UCN-01
DCC5306 Ucp1172 Novel dual inhibitor of dihydrofolate reductase (DHFR) and its functional analog, Rv2671
DCC5307 Ucph-102f Fluorescent excitatory amino acid transporter subtype 1 (EAAT1) selective inhibitor
DCC5308 Ue2316 Potent and selective 11ß-HSD1 inhibitor, improving memory, including after intracerebroventricular drug administration to the central nervous system alone
DCC5309 Ufp512 Novel selective delta-opioid receptor agonist
DCC5310 Ufr2709 Novel Nicotinic Acetylcholine Receptor Antagonist, Inhibiting Nicotine Reward and Decreases Anxiety and Decreasing Ethanol Intake in Alcohol-Preferring Rats
DCC5311 Ugm-in-1 Novel inhibitor of UGM, impeding C. glutamicum growth
DCC5312 Ugm-in-2 Novel inhibitor of UGM, impeding C. glutamicum growth
DCC5313 Uic-94003 Novel potent human immunodeficiency virus type 1 (HIV-1) protease inhibito
DCC5314 Uk-447841 Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD)
DCC5315 Uk-505749 Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD)
DCC5316 Ukcp-110 Potent VMAT2 inhibitor
DCC5317 Ul-766 Novel chemically stable fluorescent marker of the ureter
DCC5318 Um1024 Novel Vaccine Adjuvant for Mycobacterium tuberculosis
DCC5319 Umb103 Novel potent and selective dual PLK1 and BRD4 inhibitor, inducing apoptosis in pediatric tumor cell lines, leading to significant tumor regression
DCC5320 Umb298 Novel, Potent, and Selective CBP/P300 Inhibitor
DCC5321 Umc160 Novel Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitor
DCC5322 Um-c162 Novel anti-virulence agent, rescuing nematodes from a Staphylococcus aureus infection and preventing the formation of biofilm in a dose-dependent manner without interfering with bacterial viability
DCC5323 Unag Ligand Novel fluorescent UnaG ligand, binding UnaG with high affinity (Kd = 3 nM) to induce a 2.5-fold fluorescence intensity enhancement and a 10 nm red shift
DCC5324 Unbs3157 Novel nonhematotoxic DNA intercalating agent with potent antitumor activity, inducing apoptosis via inhibition of key proteins in the PI3K/Akt/mTOR signaling pathway
DCC5325 Unc0737 Featured UNC0737 is a negative control of UNC0638 and the N-methyl analog of UNC0638. UNC0737 was designed to eliminate the hydrogen bond interaction seen in the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino group at the 4-position of UNC0224's quinazoline ring3. UNC0737 was >300-fold less potent than UNC0638 in G9a and GLP biochemical assays. As expected, UNC0737 was a poor inhibitor of G9a (IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled assays.
DCC5326 Unc0965 Biotinylated UNC0638, enabling chemiprecipitation of G9a from whole cell lysates
DCC5327 Unc10112731 Novel MYC protein stablizer, increasing the abundance of endogenous MYC proteintargeting the receptor tyrosine kinases KIT and platelet-derived growth factor receptor α (PDGFRα)

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X